Navigation Links
Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Date:7/23/2009

VANCOUVER, July 23 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (collectively, the "Offering Documents"). The Offering Documents, when made final and / or declared effective, will allow Angiotech to make offerings of Common shares, Class I Preference shares, debt securities, warrants or units for initial aggregate proceeds of up to US$250 million during the next 25 months to potential purchasers in British Columbia, Ontario and the United States. Angiotech intends to use the proceeds from any such offering for general corporate purposes, including funding research and development programs, capital expenditures, working capital and/or repayment or refinancing of the Company's outstanding indebtedness, except as otherwise indicated in the applicable prospectus supplement related to any such offering.

A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... Chester, PA (PRWEB) May 22, 2013 ... company as Fermentation Manager. Mr. McErlean has an ... variety of leadership positions throughout his career. ... “We are very pleased to have Mike join our ... newly installed large scale fermentation and downstream ...
(Date:5/22/2013)... 22, 2013 The ability to ... the information they encode. There are now a ... sequencing of ribosome protected fragments) that dramatically expand ... Keynote speakers include Dr. Jonathan Weissman, an Investigator ... Howard Hughes Medical Institute, who will present recent ...
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... (OTC Bulletin Board: BSTC), a biopharmaceutical company,developing first ... Thomas Wegman, will present at the upcoming Piper,Jaffray ... 2, 2008, at,4:30pm ET at the New York ... A live webcast ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... District of New Jersey last night granted AstraZeneca Pharmaceuticals, ... of Teva,s generic Pulmicort Respules(R) (budesonide inhaled solution). ... agreed and that it too would halt all sales ...
... Inc.,(Nasdaq: NBIX ) announced today that Kevin ... be presenting at the 20th,Annual Piper Jaffray Health Care ... The live "fireside chat" presentation takes place ... /10:30 a.m. Pacific Time (PT). The,presentation will be simultaneously ...
Cached Biology Technology:Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension 2
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... Michigan Water Center today awarded 12 research grants, ... and protection efforts. , The two-year grants of ... efforts to track the remediation of harmful algae ... non-native weedy plant invasions; study chromosomal damage in ... restoration activities. , The grants were awarded to ...
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Fueling fitness on the final frontier 2
... risky for some,breastfeeding mothers, according to researchers at The ... Children (SickKids) in Toronto.,Lead author Dr. Gideon Koren published ... which suggests that the codeine used in some ... fatal results for infants when ingested by some breastfeeding ...
... NH Embracing the belief that an interdisciplinary and ... advancing science and influencing policy, a group of experts ... how mercury moves through the marine ecosystem and into ... Metals Research Program convened the group of 43 leading ...
... protect people from heart attacks. But to do that they ... Earlier this year, a team led by William Maisel at ... be used to modify wireless communications from a pacemaker ( ... these signals to monitor and adjust the implanted device, but ...
Cached Biology News:Codeine not safe for all breastfeeding moms and their babies 2Dartmouth workshop sets research agenda for environmental mercury 2How to stop a new type of heart attack 2
...
... The CopyControl™ PCR Cloning Kits are designed to ... ensure that all PCR products, regardless of sequence ... All PCR products including those that are difficult ... that may be unstable or code for potentially ...
... 40 reactions. Optimized for the rapid ... products with blunt or sticky ends.Replaces ... consistently better signal-to-noise ratios and as ... generated by proof-reading thermostable polymerases are ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Biology Products: